Contrasting responses by basal ganglia met-enkephalin systems to low and high doses of methamphetamine in a rat model

Journal of Neurochemistry

Volumn 76, Issue 3, 2001, Pages 721-729

  Alburges, Mario E ^a   Keefe, Kristin A ^a   Hanson, Glen R ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Dopamine; Eticlopride; Met enkephalin; Methamphetamine; SCH 23390; Striatum

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; ETICLOPRIDE; METENKEPHALIN; METHAMPHETAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; GLOBUS PALLIDUS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; RAT; SUBSTANTIA NIGRA;

ANIMALS; BASAL GANGLIA; CORPUS STRIATUM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENKEPHALIN, METHIONINE; GLOBUS PALLIDUS; MALE; METHAMPHETAMINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SUBSTANTIA NIGRA; TIME FACTORS;

ANIMALIA;

EID: 0035152855     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2001.00043.x     Document Type: Article

References (50)

1. Involvement of dopamine D-1 and D-2 receptors in the regulation of proenkephalin mRNA abundance in the striatum and accumbens of the rat brain
2. Opposing actions of D-1 and D-2 dopamine receptor-mediated alterations of cyclic AMP formation during the amphetamine-induced release of endogenous dopamine in vitro
3. Effects of naloxone on methamphetamine and apomorphine stereotypy and on haloperidol catalepsy in rats
4. Medial forebrain bundle stimulation or D-2 dopamine receptor activation increases, preproenkephalin mRNA in rat striatum
5. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
6. Up-regulation of neurotensin mRNA in the rat striatum after acute methamphetamine treatment
7. Dextro-naloxone counteracts amphetamine-induced hyperactivity
8. Continuous treatment with the D-2 dopamine receptor agonist quinpirole decreases D-2 dopamine receptors, D-2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum
9. Excitatory and inhibitory dopaminergic regulation of oxytocin secretion in the lactating rat, evidence for respective mediation by D-1 and D-2 dopamine receptor subtypes
10. The effect of intrastriatal application of directly and indirectly acting dopamine agonists and antagonists on the in vivo release of acetylcholine measured by brain microdialysis. The importance of the post-surgery interval
11. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats
12. Rapid and reversible effects of methamphetamine on dopamine transporters
13. Met-enkephalin concentrations in striatum respond reciprocally to alterations in dopamine neurotransmission
14. Recent advances in the molecular biology of dopamine receptors
15. Differential effects of antipsychotic and psychotomimetic drugs on neurotensin systems of discrete extrapyramidal and limbic regions
16. Dopamine D-1 regulation of caudate neurotensin mRNA in the presence or absence of the nigrostriatal dopamine pathway
17. Characterization of methamphetamine effects on the striatal-nigral dynorphin system
18. Response of mesolimbic substance P systems to methamphetamine treatment
19. Responses of limbic and extrapyramidal neurotensin systems to stimulants of abuse: Involvement of dopaminergic mechanisms. The neurobiology of neurotensin
20. Evidence for dual mechanisms involved in methamphetamine-induced increases in striatal preprotachykinin mRNA
21. Specificity in the projection patterns of accumbal core and shell in the rat
22. Influence of a carrier transport process on in vivo release and metabolism of dopamine: Dependence on extracellular Na+
23. Differential modulation of striatonigral dynorphin and enkephalin by dopamine receptor subtypes
24. Dopamine decreases striatal en kephalin turnover and proenkephalin messenger RNA abundance via D-2 receptor activation in primary striatal cell cultures
25. Dual determination of extracellular cholecystokinin and neurotensin fragments in rat forebrain: Microdialysis combined with a sequential multiple antigen radioimmunoassay
26. CNS stimulants: Two distinct mechanisms of action for amphetamine-like drugs
27. Changes in the limbic neurotensin systems induced by dopaminergic drugs
28. Role of dopamine D-1 and D-2 receptors in the regulation of neurotensin systems of the neostriatum and nucleus accumbens
29. Induction of neurotensin and c-fos mRNA in distinct subregions of rat neostriatum after acute methamphetamine: Comparison with acute haloperidol effects
30. A novel method for producing anti-peptide antibodies
31. Delta opioid receptors regulate calcium-dependent, amphetamine-evoked glutamate levels in the rat striatum: An in vivo microdialysis study
32. Increases of substance P-like immunoreactivity within striatal-nigral structures after subacute methamphetamine treatment
33. Naloxone reduces the neurochemical and behavioral effects of amphetamine but not those of cocaine
34. Escalating dose-binge stimulant exposure: Relationship between emergent behavioral profile and differential caudate-putamen and nucleus accumbens of dopamine responses
35. N-methyl-D-aspartate receptors mediate dopamine-introduced changes in extrapyramidal and limbic dynorphin systems
36. Acute amphetamine or methamphetamine alters opioid peptide mRNA expression in rat striatum
37. Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior
38. Enkephalin regulates acute D-2 dopamine receptor antagonist-induced immediate-early gene expression in striatal neurons
39. Synthetic peptide vaccine design: Synthesis and properties of a high-density multiple antigenic peptide system
40. Acute effects of D-1 and D-2 dopamine receptor agonist and antagonist drugs on basal ganglia [met5]- and [leu5]-enkephalin and neurotensin content in the rat
41. Opioid receptor agonists selective for mu and kappa receptors attenuate methamphetamine-induced behavioral sensitization in the mouse
42. DAMGO ([D-ala2,NMePhe4,Gly-ol] enkephalin), but not DPLPE ([D-Pen2,L-Pen5] enkephalin), specifically inhibits methamphetamine-induced behavioral responses in the mouse
43. Enkephalin-containing nerve cell bodies in the substantia nigra of the rat: Demonstration by immunohistochemistry and in situ hybridization
44. Afferent connections of the rat substantia nigra pars lateralis with special reference to peptide-containing neurons of the amygdalo-nigral pathway
45. Dose-dependent alteration in zif/268 and preprodynorphin mRNA expression induced by amphetamine and methamphetamine in rat forebrain
46. D-1 and D-2 receptor regulation of preproenkephalin and preprodynorphin mRNA in rat striatum following acute injection of amphetamine or methamphetamine
47. The full D-1 dopamine receptor agonist SKF-82958 induces neuropeptide mRNA in the normosensitive striatum of rats: Regulation of D-1/D-2 interactions by muscarinic receptors